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24. Standard curves for blood Interferon concentration were
generated for given doses. Interferon levels were measured
daily for 7 days in all patients using ELISA assay speciﬁc to
used Interferon molecule.
Results: All samples were reactive with ELISA assay.
Concentration and assay results correlated in a linearly
manner. Standard curve was generated for each run of
samples for all patients. Interferon level has been traced
from 1st to 7th day.
There was signiﬁcant inter-patient variation in levels
of detectable interferon for both responders and non-
responders. In all 7 cases with sustained viral response,
interferon levels were low or undetectable in days 6 and
7. Even one patient whose interferon level was traced in
the 4th day was also a responder. There is no signiﬁcant
difference between responders and non-responders either
in daily median concentration through-out the 7 days, nor
in the association of viral load or genotype to interferon
concentration with viral clearance.
Conclusion: Tracing of single dose Reiferon Retard®
demonstrated detectable interferon levels up to 7 days.
Although interferon levels were low or undetectable in 7
out of 14 cases at days 6 and 7, sustained viral response
was achieved in all cases. Suggested explanation: interferon
attaches to cell receptors by PEG molecule and acts on
cellular level till next dose is received. There might be
other host factors predicting interferon response other than
pharmacokinetics of PEG interferon.
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Background: Despite the fact that hepatitis C virus (HCV)
is a common infection in China, there is little information
on prevalence rates, particularly in the rural area of Jilin
province. Blood transfusions and more intravenous drug used
are risk factors of spreading the virus. In order to investigate
HCV infection status and related factors associated with HCV
infections among rural people in Jilin province, a cross-
sectional population-based survey was conducted.
Methods: Blood samples from 2,849 subjects were analyzed
for Anti-HCV, hematological, blood chemistry and HCV-RNA
tests. A standardized questionnaire concerning the socio-
demographic characteristics and potential risk factors was
carried out.
Results: The HCV infection was detected in 33.2%
(947/2849) of subjects at this survey. HCV RNA were
detected in 873 HCV-infected individuals, 18.8% (164) of
HCV-infected individuals has a spontaneous clearance of
virus infection. 57.7% (409/709) of HCV-infected individuals
were detected to have high-levels of the viral load (>400000
IU/ml). HCV genotypes of 252 samples were examined,
142 (56.3%) individuals had the infection of subtype 1b;
101 (40.1%) had subtype 2a; 9 (3.6%) had a co-infection
of subtype 1b/2a. Multivariate analyses revealed that risk
factors related to HCV infection were unsafe injections (OR:
11.7; 95%CI: 5.6 24.2), caffeine-sodium benzoate injections
(OR: 7.1; 95%CI: 4.4 11.3), age (40years, OR: 5.8; 95%CI:
3.9 8.1) and sex (in male, OR: 1.8; 95%CI: 1.5 2.2).
Conclusion: The most common source of HCV spreading
was a caffeine-sodium benzoate injection. Subtype 1b and
2a are predominant HCV genotypes in the area of Jilin
province. Public health measures should be taken to reduce
the abuse of intravenous injections and exposure of unsafe
injections.
PP-143 Hepatitis C virus genotype and subtype
distribution in China
W. Ju1 *, S. Yang1, Q. Wang1, H.C. Xing1, W. Xie1, Y. Xie1,
J. Cheng1. 1Beijing Ditan Hospital, Capital Medical
University, China
Background: Hepatitis C virus (HCV) heterogeneity accounts
for the lack of successful anti-viral therapy in some patients.
The object of this study is to determine HCV genotype and
subtype distribution in China mainland.
Methods: A total of 788 HCV RNA positive serum samples
were collected from chronic HCV infected patients from
14 geographic areas in China during 2009.10 2011.4.
Nucleotide sequence analysis of the NS5B and/or CORE-
E1 regions of the HCV genome was performed on samples.
Phylogenetic analysis was used for analysis of HCV genotype
and subtype.
Result: HCV genotype was determined in 747 samples
[94.80% (747/788)]. Genotype 1, 2, 3 and 6 were detected,
at frequencies of 73.49%, 18.88%, 4.95% and 2.68%,
respectively. No genotype 4 and 5 strains were found.
We detected subtypes 1b, 2a, 3a, 6a, 3b, 6n, and 1a
at frequencies of 73.09%, 18.88%, 3.21%, 2.14%, 1.74%,
0.54%, and 0.40%, respectively. Subtype 1b was the most
predominant [73.09% (546/747)] followed by 2a [18.88%
(141/747)].
Conclusion: This study demonstrated a genetic
heterogeneity of HCV infection in China, with at least
four HCV genotypes and seven subtypes. Clinical trials
of direct anti-HCV agents should consider this genetic
heterogeneity.
PP-144 NS5ATP9 contributes to inhibition of cell
proliferation by NS5A
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HCV NS5A is a remarkable protein as it clearly plays multiple
roles in mediating viral replication, host-cell interactions,
and viral pathogenesis. But on the impact of cell growth,
there were different study results. NS5ATP9, also known as
p15PAF, L5, OEACT-1, and KIAA0101, was ﬁrst identiﬁed as
a proliferating cell nuclear antigen-binding protein. Earlier
studies have shown that it might play an important role
in HCV infection. In the present study, we showed that
overexpression of NS5ATP9 inhibited the proliferation of HCC
cells, whereas knockdown of NS5ATP9 by interfering RNA
(RNAi) promoted the growth of HCC cells. Under conditions
of NS5A overexpression, RNAi targeting of NS5ATP9 could
reverse the inhibition of HCC cell proliferation by NS5A,
suggesting that NS5ATP9 could be an anti-oncogene that
plays an important role in the suppression of cell growth
mediated by HCV NS5A via MEK/ERK signal pathway.
These ﬁndings may provide new insight into the NS5A and
NS5ATP9.
PP-145 BST2/Tetherin inhibits hepatitis C virus release
from human hepatoma cells
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Research, China
Background: Hepatitis C virus (HCV) infection is a common
cause of chronic hepatitis and is currently treated with
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alpha interferon (IFN-a)-based therapies. However, the
antiviral mechanism of the cytokine against HCV remains
to be understood.
Methods: Established Huh7.5-BST2 cell lines were infected
with HCV at low (0.05) and high (3) MOI. Fluorescent
immunostaining, western blot, northern blot and viral titer
detection were used to analyze the dynamics of HCV
infection and virion production. siRNA targeting the mRNA
of BST2 was transfected into IFN-a treated Huh7.5 cells to
evaluate the role of BST2 on the effect of IFN-a against
HCV. High density (100% conﬂuent) and low density (25%
conﬂuent) cells were infected with HCV (MOI 0.05) with or
without CD81 antibody to test if BST2 inhibits HCV cell to
cell spread.
Results: We found that expression of an IFN-induced
cell membrane protein BST2 in Huh7.5 cells did not
apparently affect the efﬁciency of HCV infection and
genome replication, but signiﬁcantly reduced the yield
of virion production from the infected cells. In addition,
BST2 also dramatically inhibited the cell-to-cell transmission
of HCV in cultured Huh7.5 monolayers. Furthermore,
we demonstrated that inhibition of IFN-a-induced BST2
expression in Huh7.5 cells by siRNA technology compromised
the antiviral response of the cytokine against HCV.
Conclusions: Our results imply that BST2 is a functional
mediator of IFN response against HCV infection and inhibits
the release of HCV virions, which presumably buds from the
endoplasmic reticulum, but not plasma membrane.
PP-146 The effect of hepatitis C virus nonstructural 2
transactivated protein (NS2TP) expression on
the HepG2 cell growth
Q. Wang1 *, X.Q. Li2, Y. Li3, J. Cheng1. 1Department of
Infection Disease, Beijing Ditan Hospital, Capital Medical
University, 2The ﬁrst afﬁliated hospital, Medical school of
Xi’an Jiaotong University, 3Beijing Center for Physical and
Chemical Analysis, China
Full length NS2TP gene was ampliﬁed by PCR,
using prokaryotic expression plasmid pET32a(+)-NS2TP as
template, and cloned into the eukaryotic expressing
vector pEGFP-C1by DNA recombination technique. The
recombinant plasmid was identiﬁed by restriction enzyme
digestion, polymerase chain reaction and direct sequencing.
Then both the recombinant plasmid pEGFP-C1-NS2TP and
the control vector pEGFP-C1 were used to transfect HepG2
cell with Lipofectin 2000. After 30 h, the cells were
collected and NS2TP gene expression was proved by Western
blot analysis. Under the same culture conditions, both of
the HepG2 cell transfected with pEGFPC1-NS2TP and pEGFP-
C1 were collected after 30 h postransfection. Celltiter-Glo
luminescent cell viability assay showed that the growth of
hepG2 cells transfected with NS2TP gene was dramatically
inhibited compared with the parent hepG2 cells. These
results indicated that NS2TP could affect the cell growth of
HepG2 cell.
PP-147 Impact of gender on virologic responses rates in
genotype 1 chronic hepatitis C patients with
peginterferon alfa-2a and ribavirin treatment
J.-W. Yu1 *, L.-J. Sun1. 1Department of Infectious Diseases,
Second Afﬁliated Hospital, Harbin Medical University,
China
Objective: To study the impact of gender on virologic
responses rates in genotype 1 CHC patients.
Methods: A matched retrospective cohort on 630 patients
treated with peginterferon and ribavirin was conducted.
The virologic response rates were compared between male
and female. The inﬂuential factors on SVR were studied
by multivariate analysis. In patients aged <40 years group,
the SVR rate of female was signiﬁcantly higher than that
of male (75.0%, 75/100 vs 54.0%, 54/100; P = 0.002); in
patients aged 40 50 years group, there was no signiﬁcant
difference in the SVR rate between male and female
(50.5%, 53/105 vs 54.3%, 57/105; P = 0.580); in patients aged
51 60 years group, the SVR rate of female was signiﬁcantly
lower than that of male (33.6%, 37/110 vs 48.2%, 53/110;
P = 0.028). In multivariate logistic regression analysis, the
independent factors associated with SVR of patients aged
51 60 years were sex (P = 0.013), 80% of planned ribavirin
dose (P = 0.008) and presence of RVR (P = 0.001).
Conclusions: In patients aged <40 years group, the SVR rate
of female is higher than that of male; in patients aged
40 50 years group, they share similar SVR rates; in patients
aged 51 60 years group the SVR rate of female is lower than
that of male.
PP-148 The efﬁcacy and inﬂuential factors of treatment
with peginterferon alfa-2a and ribavirin in
elderly patients with chronic hepatitis C
J.-W. Yu1 *, L.-J. Sun1. 1Department of Infectious Diseases,
Second Afﬁliated Hospital, Harbin Medical University,
China
To evaluate the efﬁcacy of treatment with peginterferon
alfa-2a and ribavirin in elderly CHC patients and study the
inﬂuential factors related to SVR. The patients were divided
into two groups according to age: patients aged 65 years
(n = 140) and patients aged <65 years (n = 277). The virologic
response rates of two groups were compared.
Results: For genotype 1, patients aged 65 years had
signiﬁcantly higher relapse rate (50.0%, 42/84 vs 29.2%,
52/178; P = 0.001) and lower SVR rate (40.0%, 42/105 vs
60.0%, 126/210; P = 0.001) than patients aged <65 years.
For genotype 1, in patients aged 65 years, the SVR rate
of female patients was signiﬁcantly lower than that of
male patients (28.6%, 12/42 vs 47.6%, 30/63; P = 0.004).
In multivariate logistic regression analysis, the independent
factors associated with SVR of patients aged 65 years were
sex (P = 0.020), genotypes (P = 0.005), ribavirin reduction or
discontinuation (P = 0.009) and presence of rapid virologic
response (RVR) (P = 0.001).
Conclusions: The SVR rate of patients aged  65 years with
genotype 1 is low. Among patients 65 years old, genotype
2 patients and genotype 1 patients with a low baseline viral
load or achieving RVR or male may beneﬁt from combination
therapy.
PP-149 Role of polymorphisms of IL28B in HCV
treatment effect of pegylated-interferon and
ribavirin: a meta analysis
Z.F. Jia1 *, J. Jiang1, X.M. Chi2, J.Q. Niu2. 1Division of
Clinical Epidemiology, First Hospital of Jilin University,
Changchun, China, 2Department of Hepatology, First
Hospital of Jilin university, Changchun, China
Objective: In 2009, three works published almost at
the same time studied the association between single
nucleotide polymorphisms near IL28B gene region and
treatment effect of pegylated-interferon (PegIFN) and
ribavirin (RVB) in HCV-infected patients. Many studies on
this issue with different HCV genotype and ethnic subjects
published subsequently. However, the conclusions about the
role of these polymorphisms are not identical. The aim
of this study was to quantify the impact of the IL28B
polymorphisms on the effect of HCV standard treatment
using meta-analysis based method.
